Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer
Abstract Many non-small cell lung cancer (NSCLC) patients remain unresponsive to the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, like anti-PD-1/PD-L1 antibodies. While interleukin (IL)-1β is known to promote lung cancer growth in humans and mice, we show h...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Portfolio
2025-11-01
|
| Schriftenreihe: | Nature Communications |
| Online-Zugang: | https://doi.org/10.1038/s41467-025-64839-4 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
